On January 11, 2021 Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, reported a strategic collaboration with Almac Diagnostic Services to enhance opportunities for clinical trial development and companion diagnostic (CDx) projects (Press release, Almac, JAN 11, 2021, View Source [SID1234575423]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PGDx and Almac Diagnostic Services will focus on providing access to tumor profiling assays for both tissue and plasma samples, specifically, PGDx elio tissue complete and PGDx elio plasma resolve. This collaboration will combine Almac’s world-class genomics services and expertise in development and delivery of molecular diagnostics with PGDx’s leadership in cancer genomics to accelerate solutions that will deliver precision medicine to more patients.

"We are proud to enter into this strategic collaboration with Almac. Their longstanding reputation for providing high quality lab services to patients worldwide, along with their proven track record of implementing new technologies make this partnership ideal," said Megan Bailey, CEO, PGDx. "As we continue our quest to empower the fight against cancer, collaborating with Almac will allow us to deliver precision medicine solutions to a broader population and advance innovations in next-generation sequencing technology."

Michael Sloan, Global Vice President of Commercial Operations, Almac Diagnostic Services said: "This collaboration with PGDx will enable Almac to provide our Pharmaceutical and Biotech partners with tissue and liquid biopsy options to support their translational research, clinical trials and CDx development requirements. The assay panels PGDx have developed will allow our clients to access world-class next generation sequencing science and bioinformatics solutions."

On January 11, 2021 Humanigen, Inc. Presented the corporate Presentation (Presentation, Humanigen, JAN 11, 2021, View Source [SID1234575164]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 11, 2021 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, reported that its management team will attend the following key investor and scientific conferences in the coming months (Press release, Onxeo, JAN 11, 2021, View Source [SID1234575009]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect 2021 Conference
January 11-14, 2021 (virtual conference)

For more information and to register, click here

Biomed Event
January 26-27, 2021 (virtual conference)

For more information and to register, click here

4TH Annual PARP & DDR Inhibitors Summit
January 26-28, 2021 (virtual conference)

For more information, click here

Edison Open House Global Healthcare 2021
January 26-28 2021 (virtual conference)

For more information and to register, click here

AACR Annual Meeting 2021
April 9-14, 2021 (virtual conference)

On January 11, 2021 Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that it has entered into an agreement with Mackie Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and National Bank Financial Inc. (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 14,546,000 units of the Company (the "Units") for aggregate gross proceeds to the Company of US$40,001,500 (equivalent to approximately C$51,081,915) (the "Offering") at a price of US$2.75 per Unit (equivalent to approximately C$3.51 per Unit) (Press release, Theratechnologies, JAN 11, 2021, View Source [SID1234574983]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each Unit shall be comprised of one common share of the Company (each a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of US$3.18 (equivalent to approximately C$4.06) at any time up to 36 months from the closing of the Offering.

On January 11, 2021 Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) ("Diffusion" or "the Company"), reported that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021 (Press release, Diffusion Pharmaceuticals, JAN 11, 2021, View Source [SID1234574782]). Conference specifics are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright BioConnect 2021 Conference
Date: January 11-14, 2021
Registration: View Source
The recorded presentation can be accessed by conference participants and the presentation deck can be accessed on the investor relations section of the Diffusion Pharmaceuticals’ website.